The Food and Drug Administration has determined the shortage of semaglutide injection products is resolved, and that it does not intend to take action against:
Pharmacies compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved product until April 22, 2025; and
Outsourcing facilities compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved drug product until May 22, 2025.
FDA stated that it may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe.
NCPA will keep its members appraised of developments.
